首页 | 本学科首页   官方微博 | 高级检索  
检索        

白介素35在支气管哮喘中的作用机制
引用本文:顾香,陈吉泉,李兵.白介素35在支气管哮喘中的作用机制[J].中华哮喘杂志(电子版),2012,6(4):277-280.
作者姓名:顾香  陈吉泉  李兵
作者单位:第二军医大学长征医院呼吸内科,上海,200003
基金项目:上海市科学技术委员会资助项目(114119a3200)
摘    要:支气管哮喘(简称哮喘)是由多种细胞和细胞因子参与的慢性呼吸道炎症性疾病,发病机制可能与Th1/Th2细胞因子失衡、CD4+CD25+ T细胞(调节性T细胞,简称Tregs)及Th17/IL-17等异常有关。白介素35是一种新发现的细胞因子,其与Tregs及Th17/IL-17等免疫调节功能密切相关,通过多种途径参与哮喘的发病和调节,有望成为哮喘的治疗新靶点。本文对此相关研究作一综述

关 键 词:白介素35  哮喘  发病机制  治疗

Role of interleukin-35 in the mechanism of bronchial asthma
GU Xiang , CHEN Ji-quan , LI Bing.Role of interleukin-35 in the mechanism of bronchial asthma[J].Chinese Journal of Asthma(Electronic Version),2012,6(4):277-280.
Authors:GU Xiang  CHEN Ji-quan  LI Bing
Institution:.Department of Respiratory Medicine, Changzheng Hospital of Second Military Medical University, Shanghai 200003, China
Abstract:Bronchial asthma (asthma) is a chronic inflammatory airway disease involved in many cytokines, the mechanism may be related with the imbalance of Th1/Th2 cells or the abnormalities of CD4+CD25+T cells, Th17/IL-17 and so on. Interleukin-35 (IL-35) is a newly discovered cytokine, which is closely related to the immune function of Th17/IL-17 and Tregs. IL-35 may be involved in the pathogenesis of asthma, which is expected to become a new target for the treatment of asthma. This review describes the relative researches on IL-35.
Keywords:Interleukin-35  Asthma  Pathogenesis  Treatment
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号